March 3, 2026

Beyond Diuresis and Glycemic Control: Comparative Analysis of Sodiumglucose Cotransporter-2 Inhibitors (SGLT2i) vs. Furosemide and Metforminin Heart Failure (HF) Patients with Type 2 Diabetes Mellitus (T2DM) Using the TriNetX Database

Key Points

Lower mortality observed with SGLT2 inhibitors compared to furosemide and metformin in heart failure patients.
SGLT2i usage led to fewer hospitalizations than traditional diuretics and diabetes medications.

Structured PICO

Does SGLT2i use reduce mortality and hospitalizations compared to furosemide and metformin in patients with heart failure and type 2 diabetes mellitus?

Population

Patients with heart failure (HF) and type 2 diabetes mellitus (T2DM) from the TriNetX Database

Intervention

Sodium-glucose cotransporter-2 inhibitors (SGLT2i)

Comparator

Furosemide and metformin

Outcome

Mortality and hospitalizationshard clinical

Real-world observational data suggests SGLT2 inhibitors are associated with lower mortality and hospitalizations compared to furosemide and metformin in patients with HF and T2DM.

Abstract

In this real-world analysis, SGLT2i use was associated with lower mortality and fewer hospitalizations compared with furosemide and metformin in patients with HF and T2DM. These findings should be interpreted as associations rather than causal effects due to the observational design and potential residual confounding. The results are hypothesis-generating and directionally consistent with prior randomized evidence.

Bookmark

Cite This Study

Daise et al. (Tue,) studied this question.

synapsesocial.com/papers/69a75b4ac6e9836116a2261b https://doi.org/https://doi.org/10.2174/0118715257413814251201065911

Bookmark